$JBS

JBS N.V. (JBS): Results of Operations and Financial Condition

JBS N.V. (JBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ea030137401ex99-1.htm EARNINGS RELEASE ANNOUNCING JBS N.V.'S RESULTS FOR THE QUARTER ENDED JUNE 30, 2026 Exhibit 99.1 JBS REPORTS SECOND QUARTER 2026 RESULTS August 10, 2026 – JBS N.V. (NYSE: JBS; B3: JBSS32), announces today its 2Q26 results. The numbers reported herei

Original reporting
Published Aug 11, 2026, 1:16 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 10:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$JBS
Neutral
medium confidence
Mentioned
$JBS
Relevance
8/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JBSNeutralMed
01

Why it matters

Traders can update models using the reported quarterly datapoints (sales, adjusted EBITDA, adjusted operating income, EPS) and leverage/coverage metrics, and reassess near-term margin drivers tied to cattle availability and import restrictions.

02

Market read

This is a primary quarterly earnings disclosure with detailed profitability and leverage metrics, plus operational actions and a dated expectation for Mexico live cattle import resumption (Aug 24).

03

What to watch

Non-recurring items (tender offer premiums/costs, antitrust settlements, bargain purchase gain) may distort headline net income and could lead to differing investor interpretations of underlying earnings power.

Relevance 8/10Novelty 7/10Timing: after-hours filing on Aug 10, 2026 for 2Q26 results

Background

SEC 8-K Item 2.02 includes Exhibit 99.1 with JBS second-quarter 2026 financial results under IFRS and US GAAP non-GAAP reconciliations, plus Item 5.02 director/officer and compensatory arrangements.

Company-level read

Ticker impact

$JBSNeutralMedium confidence
Context

JBS filed an 8-K with 2Q26 results showing net sales of $23.9B and adjusted EBITDA down year over year, plus leverage at 3.1x.

Expected impact

Near-term bias depends on how investors weigh revenue growth versus the profitability decline and leverage slightly above target; operational restructuring may be viewed as cost discipline.

Evidence & confidence

The filing provides concrete quarterly financials (sales, adjusted EBITDA, adjusted operating income, EPS) and balance-sheet metrics (leverage, interest coverage) plus management commentary and restructuring steps, which are typically market-moving for a quarterly earnings release.

Market effects

Beef and poultry margins appear pressured by cattle availability and commodity pricing, with JBS citing live cattle price dynamics and cutout spread pressure.

US operations face constrained supply from restricted Mexico live cattle imports, with expected gradual resumption starting Aug 24.

Brazil and export demand (including China quota fill) are highlighted as key offsets to cost pressures and regional conflicts affecting foodservice and pork margins.

Counterpoint

Revenue and EBITDA remain sizable, and management highlights sequential improvement in most business units plus cost actions (plant closures, unit consolidation) that could stabilize margins.

Key entities

  • JBS N.V.

    Reported 2Q26 results, including net sales $23.9B, adjusted EBITDA down year over year, net loss of $102M, leverage 3.1x, and operational restructuring actions.

  • Beef USA

    JBS merged Fed Beef, Regional Beef, and Case Ready into a single structure to simplify operations and improve efficiency.

  • Souderton, Pennsylvania and Memphis, Tennessee plants

    JBS announced closure of two plants (processing in Souderton and case ready in Memphis) with production absorbed by other US plants.

Related articles

$JBSMed

JBS Q2 Slips To Loss, Adj. EBITDA Drops; Stock Down

JBS N.V. reported a Q2 2026 net loss attributable to shareholders of $102.1 million, or $0.10 per share, versus net income of $528.1 million, or $0.48 per share a year earlier, despite higher net sales of $23.9 billion. Adjusted EBITDA fell 18.5% to $1.429 billion. JBS shares were down about 3% in NYSE overnight trading at $13.00.

$JBSMed

Why is JBS stock sliding today?

JBS NV shares fell 5.7% to $13.43 as investors weighed earnings risk ahead of its Q2 2026 results after the close. Analysts expect EPS of about $0.33 on revenue near $22.77B, implying roughly a 40% year-over-year profitability drop. The stock also reacted to a leadership change: Wesley Batista Filho to become Global CEO in Jan 2027.

$JBSMedAI 8/10

Danantara takes stake in JBS Australia and NZ operations

Danantara Investment Management will buy a 25% stake in JBS’s Australia and New Zealand operations, investing USD 2.5 billion (AUD 3.5 billion). The partnership may add up to USD 2.5 billion more capacity, targeting acquisitions and greenfield growth across Indonesia, Australia, New Zealand and Southeast Asia. Deal is subject to Australian regulatory approvals.

$JBSMedAI 9/10

JBS Signs Deal Worth Up to US$5 Billion in Indonesia

JBS SA (NYSE: JBS) said it signed a binding agreement with PT Danantara Investment Management, an arm of Indonesia’s sovereign wealth fund, to form an Asia-Pacific protein joint venture worth up to US$5 billion. Danantara will inject US$2.5 billion equity for a 25% stake in two phases, with JBS contributing its Australia and New Zealand operations. The venture may later raise up to US$2.5 billion debt, subject to approvals.

$JBSMedAI 8/10

JBS targets Southeast Asia growth with $2.5 billion deal

JBS said it will expand in Indonesia, Australia and New Zealand via a partnership with Danantara Investment Management. Danantara will invest $2.5 billion for a 25% equity stake in JBS’s Australia and New Zealand operations, subject to Australian regulatory approvals. JBS expects up to $5 billion total capital for future growth.